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 Objectives To estimate the point prevalence of primary hyperaldosteronism 
in a government out-patient setting and to compare associated 
patient characteristics with those having essential hypertension.
 Design Case series with external comparison.
 Setting A single public hospital (Caritas Medical Centre) and all five 
associated general out-patient clinics in Sham Shui Po district in 
Hong Kong.
 Patients All patients with confirmed primary hyperaldosteronism and 
randomly selected patients with essential hypertension from 
a medical specialist clinic and general out-patient clinics, 
retrieved from a computer database for the period January 2007 
to December 2008.
 Main outcome measures Estimated point prevalence of primary hyperaldosteronism 
among hypertensive patients treated in the public sector of Sham 
Shui Po district. Patient age when hypertension was diagnosed, 
number of antihypertensive drugs used for treatment, and the 
presence of target organ damage in the patients with primary 
hyperaldosteronism and those with essential hypertension were 
compared.
 Results Among the 46 012 patients receiving antihypertensive treatment, 
49 were confirmed to have primary hyperaldosteronism. The 
estimated point prevalence of primary hyperaldosteronism 
among these hypertensive patients was 0.106% only, which 
was far smaller than figures from other countries. When 
compared with the 147 patients with essential hypertension by 
multivariate analysis, those with primary hyperaldosteronism 
were: (1) associated with longer durations of hypertension 
(odds ratio=1.14; 95% confidence interval, 1.06-1.24) despite 
being younger at the time of study, (2) likely to be taking three or 
more antihypertensive drugs (odds ratio=2.51; 95% confidence 
interval, 1.59-3.95), and (3) more likely to have left ventricular 
hypertrophy (odds ratio=5.01; 95% confidence interval, 1.83-
13.69). All primary hyperaldosteronism patients studied 
presented with hypokalaemia. The need for antihypertensive 
drugs was markedly reduced after adrenalectomy for adrenal 
adenoma.
 Conclusions Primary hyperaldosteronism, which is potentially a surgically 
curable cause of hypertension, appeared to be underdiagnosed 
in our locality. Screening by aldosterone-renin ratio of high-risk 
individuals may help improve patient outcomes.
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New knowledge added by this study
• Primary hyperaldosteronism was probably underdiagnosed among hypertensive patients in 
our locality.
• Patients with primary hyperaldosteronism are more likely to be younger and more drug-
resistant than those with essential hypertension.
Implications for clinical practice or policy
• Instead of only screening hypokalaemic hypertensive patients, we suggest screening high-
risk individuals by aldosterone-renin ratio, especially those with young age of onset and/or 
resistant hypertension.
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Introduction
The Population Health Survey 2003-04 of the 
Department of Health revealed that around 27% of 
the population aged 15 years or above had increased 
blood pressure.1 Hypertension is the second most 
common problem encountered in Hong Kong 
primary care (10% of all health-related issues).2 It 
is commonly encountered in general out-patient 
clinics (GOPCs) accounting for 43% of attendees,3 
and medical/geriatric specialty out-patient clinics 
(SOPCs) accounting for 47% of attendees4 of the 
Hong Kong Hospital Authority, which is similar among 
all districts of Hong Kong.3 In the Sham Shui Po (SSP) 
Community Diagnoses Study conducted by the 
City University of Hong Kong in 2002, hypertension 
was the major chronic disease among residents of 
SSP, and affected 14.4% of its 372 000 residents and 
 目的 評估原發性醛固酮增多症（以下簡稱原醛症）在政府
門診的時點患病率，並把此症的患者與原發性高血壓
患者作特徵比較。
 設計 與其他醫院比較的病例系列。
 安排 香港一所公立醫院（明愛醫院）及深水埗區其餘五間
政府門診部。
 患者 從醫院的電腦檔案中抽取2007年1月至2008年12月期
間所有確診為原醛症患者的紀錄，以及從一所專科診
所及其他政府門診隨機抽樣的原發性高血壓患者的紀
錄。
 主要結果測量 估計從深水埗區公立醫院所處理的高血壓患者中出現
原醛症的時點患病率，並比較原醛症患者及高血壓
患者在以下幾方面的分別：患者確診為高血壓時的年
齡、服食降壓藥物的數量，以及是否有器官損壞的情
況。
 結果 服食降壓藥物的46 012名病人中，49人確診患有原
醛症，其時點患病率為0.106﹪，數字遠低於其他國
家。與147名原發性高血壓患者比較，多元回歸分析
結果顯示原醛症患者雖然年齡較輕，他們患有高血壓
的年期卻較長（比數比=1.14；95﹪置信區間：1.06-
1.24）。此外，原醛症患者較大機會服食多於三種或
以上降壓藥物（比數比=2.51；95﹪置信區間：1.59-
3 . 95），他們左心室肥厚的機會亦較高（比數
比=5.01；95﹪置信區間：1.83-13.69）。所有原醛症
患者均有低血鉀症，他們因腎上腺腺瘤而接受腎上腺
切除術後，都會大大減少對降壓藥物的需求。
 結論 原醛症雖會引致高血壓，但適合手術治療。在香港，
原醛症以乎出現診斷不足的情況。使用血漿醛固酮／
腎素活性比值把高風險人士進行篩檢可以改善患者的
治療結果。
高血壓華籍患者的原發性醛固酮增多症： 
香港的情況
comprised 5.3% of the total Hong Kong population.5 
Although only about 5 to 10% of patients with 
hypertension are thought to have a secondary 
form, hypertension is so common that secondary 
hypertension will be encountered frequently in 
primary care.6,7 However, the management may be 
very different if secondary hypertension is identified, 
and most importantly it is possible to offer patients 
a cure.
 It is suggested that primary hyperaldosteronism 
(PH) is a common cause of secondary hypertension. 
This is important not only because it is potentially 
curable by surgery but also because it is associated 
with higher cardiovascular morbidity and mortality 
than in age- and sex-matched patients with essential 
hypertension (EH) having the same degree of 
blood pressure elevation.8 Moreover, generally, it is 
associated with higher rates of target organ damage 
than in patients with EH.9 
 In the past, when we used to screen for 
PH in hypertensive patients with spontaneous 
hypokalaemia only, its prevalence among 
hypertensive patients was estimated to be less 
than 1%.10,11 However, recent studies using plasma 
aldosterone-renin ratio (ARR) as a screening test 
for PH in hypertensive populations suggested a 
prevalence as high as 5 to 13%, though over half of 
those affected are normokalaemic.6,12-17 According 
to the only Asian prevalence study of PH (using ARR 
screening) performed in Singapore, its estimated 
prevalence was about 5%, only 38% of whom were 
hypokalaemic.18 The ARR was calculated as the ratio 
of plasma aldosterone concentration (PAC in ng/dL) 
to plasma renin activity (in ng per mL/h). A positive 
screening test was defined as a ratio of >20 and with a 
PAC of >15 ng/dL (416 pmol/L). The latest guideline has 
also concluded that hypokalaemia has low sensitivity 
and specificity, and a low positive predictive value 
for the diagnosis of PH, and recommends ARR as 
currently the most reliable means of screening.19,20 
 The prevalence of PH may be as high as 20% 
in patients with resistant hypertension,13 and in 
about half of these patients it may be potentially 
curable, there being a unilateral aldosterone-
producing adrenal adenoma.18 A local study in Hong 
Kong confirmed that surgical excision of an adrenal 
adenoma can cure hypokalaemia in all cases and can 
cure persistent hypertension in 77% of patients.21 The 
procedure was also proven to be cost-effective in the 
long run.22 
 To date, there are no local data on the 
prevalence of PH in Hong Kong. In our locality, most 
of us screen for PH in hypertensive patients, only 
when we encounter unexplained hypokalaemia. We 
therefore undertook this study to review the situation 
in our locality, and especially from the screening for 
PH in primary care.
#		Primary	hyperaldosteronism	# 
	 Hong	Kong	Med	J		Vol	18	No	3	#	June	2012	#		www.hkmj.org	 195
 Thus, the objectives of this study were: (1) 
to estimate the point prevalence of PH among 
hypertensive patients treated in public sector in SSP; 
(2) to compare the presentation of PH patients to that 
of patients with EH; and (3) to review the outcome 
of adrenalectomy in patients with aldosterone-
producing adrenal adenomas. 
Methods
A retrospective observational study was performed 
on patients diagnosed to have PH and EH, and to 
review the situation in our locality. Patients coded 
PH (International Classification of Diseases [ICD] 
10-255.1[0-5]) or secondary hypertension (ICD10-405) 
during attendance at the Department of Medicine 
and Geriatrics of Caritas Medical Centre from 1 
January 2007 to 31 December 2008 were retrieved 
from the Clinical Data Analysis and Reporting System 
of the Hong Kong Hospital Authority. Confirmed PH 
cases were identified by record review. 
 The list of hypertensive patients who 
had received equal to or more than 180 days of 
antihypertensive drugs during the same period with 
regular follow-up in the Department of Medicine and 
Geriatrics of the Caritas Medical Centre’s SOPC and 
all the five GOPCs in SSP was retrieved. A total of 147 
patients were randomly selected as the comparison 
group to provide a 1:3 ratio for comparison. They 
were drawn by using stratified random sampling after 
excluding PH patients. The total number of patients 
drawn from each clinic was determined by its relative 
proportion of hypertensive attendees. Among the 
45 963 hypertensive patients, this amounted to 34.5% 
from the medical SOPC and 65.5% from GOPCs (Fig 
1). Different GOPCs and medical SOPCs were looking 
after various numbers of primary hypertensive 
patients. The patients from our five GOPCs were 
essentially similar to those in other districts,2 which 
were representative of hypertensive patients in 59 
GOPCs in Hong Kong. The patient list was arranged 
by numerical order of a unique out-patient number 
46 012 Patients from MSOPC and 
GOPC on antihypertensive drugs in 
Sham Shui Po district 
49 (0.1%) Patients coded 
secondary hypertension (ICD405) or 
hyperaldosteronism (ICD255.1[0-5]) 
Study group: 
All 49 patients’ record reviewed 
45 963 Patients with essential hypertension 
 15 850 (34.4%) MSOPC 
 7538 CMC GOPC
 9836 CSW GOPC
 2036 NS GOPC
 5239 SKM GOPC
 5464 WK GOPC
Comparison group:
147 Patients with essential hypertension*
 24 (16.3%) CMC GOPC
 31 (21.1%) CSW GOPC 
 6 (4.1%) NS GOPC
 17 (11.6%) SKM GOPC
 18 (12.2%) WK GOPC
 51 (34.7%) CMC MSOPC
15 899 (34.5%) from 
MSOPC 
30 113 (65.5%) from 
GOPC 
FIG 1.  Study flowchart
CMC denotes Caritas Medical Centre, GOPC general out-patient clinic, ICD International Classification of Diseases, CSW Cheung Sha 
Wan, NS Nam Shan, SKM Shek Kip Mei, WK West Kowloon, and MSOPC medical specialty out-patient clinic
* According to proportion of patients followed up in various clinics randomly selected for record review
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assigned to each patient chronologically by the 
computer during the patient’s first registration. 
Repeated sampling of the same subject was avoided 
by checking for duplicate out-patient numbers. 
Each patient was given a number according to the 
order in the list. The required patients were then 
drawn randomly using a random number generator. 
Headcount by antihypertensive treatment instead of 
headcount by ICD-10 and International Classification 
of Primary Care coding was used as the coding for 
hypertension was incomplete in SOPCs. 
 Clinical notes of PH patients and the 
comparison group (EH patients) until the last 
visit record were reviewed for demographic data, 
diagnosis, presentations, antihypertensive drug 
treatment, and the presence of target organ damage. 
The outcome of adrenalectomy was also reviewed. 
 Data were analysed by the Statistical Package 
for the Social Sciences (Windows version 16; SPSS 
Inc, Chicago [IL], US). All continuous data were 
expressed as medians or means with standard 
deviations (SDs). In univariate analysis, the t test was 
used for comparisons of continuous data while the χ2 
test was applied to comparisons of categorical data. 
In the multivariate analysis, forward stepwise logistic 
regression was used to determine the effect of socio-
demographics (gender and age) and disease (year of 
hypertension diagnosis, receipt of antihypertensive 
drugs, and presence of target organ damage) on each 
hypertension type. All estimates were accompanied 
with a 95% confidence interval (CI). Any P value of 
less than 0.05 was regarded as statistically significant. 
 The study was approved by the Clinical 
Research Ethics Committee of the Kowloon West 
Cluster of Hospital Authority of Hong Kong. 
Results
During the study period, the number of patients with 
hypertension treated in the public sector in SSP using 
headcounts based on antihypertensive treatment 
was found to be 46 012. The numbers of EH patients 
drawn from various GOPCs and SOPCs were based 
on the proportion of hypertensive patients fulfilling 
our inclusion criteria (Fig 1). 
 A total of 49 patients were confirmed to have 
PH in this period. All were Chinese. The estimated 
percentage of PH among our hypertensive patients in 
the SSP public sector was therefore 0.106% only. The 
characteristics of these 49 PH and 147 EH patients are 
shown in Table 1.
 All cases of PH were confirmed biochemically 
with baseline serum renin and aldosterone levels and 
their response to sodium loading, postural change 
and cortisol rhythm, together with radiological 
support by computed tomography of the adrenal 
glands. Among them, 19 (39%) were confirmed to 
have adrenal adenomas (Conn’s syndrome), which 
were defined as group A; 20 (41%) were confirmed 
to have bilateral adrenal hyperplasia, defined as 
group B; and the remaining 10 (20%) had no clear-cut 
subtype classification and were defined as group C. 
Adrenal venous sampling was offered to PH patients 
when the subtype classification was uncertain; nine 
out of ten declined such sampling. Adrenal venous 
sampling was performed in one case only, in which 
the right adrenal vein could not be successfully 
cannulated due to wedging. 
 Concerning their presentation, all our PH 
patients presented were investigated for unexplained 
hypokalaemic hypertension. Of the 49 PH patients, 19 
(39%) were referred from GOPCs. Five (10%) patients 
were admitted through the accident and emergency 
department for medical problems and incidentally 
found to have hypokalaemia. Three patients were 
admitted as emergency cases for a sudden rise in 
blood pressure. One patient was admitted because 
of a cerebrovascular attack, and one was referred 
from a private general practitioner for unexplained 
hypokalaemia. The other patients were being 
followed up in the Department of Medicine and 
Geriatrics of Caritas Medical Centre for medical 
reasons, including hypertension. 
 The age at diagnosis was significantly younger 
in PH than EH patients (P<0.001). The respective mean 
(SD) and median ages were 49.1 (10.9) and 49 years 
for PH patients, compared to 63.7 (12.3) and 66 years 
for those with EH. Among the PH patients, 20% had 
hypertension diagnosed before age of 40 years. The 
mean number of years with hypertension diagnosed 
was significantly higher in the PH than EH group (9.3, 
SD 5.1 years vs 6.3, SD 4.3 years).
 There was no statistically significant difference 
in the male-to-female ratio between the groups. 
 Regarding the 49 PH patients, 22 (44.9%) were 
taking three or more antihypertensive drugs for 
control of hypertension, before they received specific 
treatment for PH. Among them, six (12%) had JNC VII 
(Seventh Report of the Joint National Committee 
on Prevention, Detection, Evaluation, and Treatment 
of High Blood Pressure) stage III hypertension 
(>180/100 mm Hg) despite treatment with three 
antihypertensive drugs.23 In contrast, only 11.6% of EH 
patients were taking three or more antihypertensive 
drugs for control of their hypertension. The mean 
number of antihypertensive drugs used were 2.3 and 
1.7 for PH and EH patients, respectively (P<0.001). 
After adjusting for age and gender differences, the 
PH patients were associated with longer durations 
of diagnosed hypertension compared to EH patients 
(odds ratio [OR]=1.14; 95% CI, 1.06-1.24), despite 
being younger at the time of study (Table 2). Similarly 
they were more likely to be taking three or more 
antihypertensive drugs (OR=2.51; 95% CI, 1.59-
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TABLE 1. Characteristics of the 49 primary aldosteronism (PH) patients and 147 essentially hypertensive (EH) patients studied
Characteristic* A: 
Aldosterone-
producing adrenal 
adenoma (n=19)
B: 
Adrenal 
hyperplasia 
(n=20)
C: 
Primary 
hyperaldosteronism 
with subtype not 
classified (n=10)
PH group: 
total primary 
aldosteronism 
patients, ie 
A+ B+C (n=49)
EH group: 
essentially 
hypertensive 
patients (n=147)
P value
Age when HT was diagnosed (years)
Mean ± SD 51.2 ± 14.5 47.8 ± 8.3 48 ± 7.1 49.1 ± 10.9 63.7 ± 12.3 <0.001
Median 48 48.5 50 49 66
Range
≤30 1 0 1 2 0
31-40 3 5 0 8 5
41-50 8 7 6 21 23
51-60 2 7 3 12 32
61-70 2 1 0 3 36
71-80 3 0 0 3 45
≥81 0 0 0 0 6
Actual age at the beginning of study period (years)
Mean ± SD 59.3 ± 16.2 58.5 ± 6.2 56.6 ± 7.2 58.4 ± 11.2 70.0 ± 12.6 <0.001
Median 56 57 57 57 73
Range 31-82 49-72 39-66 31-82 42-97
Years of diagnosing HT
Mean ± SD 9.1 ± 5.8 10.7 ± 5.0 8.6 ± 3.3 9.3 ± 5.1 6.3 ± 4.3 <0.001
Median 8 9.5 7.5 8 6
Range 1-26 2-20 4-15 0-26 0-27
Sex (M/F) 0.9 1.2 2.3 1.2 1.3 0.16
No. of types of antihypertensive drugs
Mean 2.6 2.1 2.4 2.3 1.7 <0.001
Proportion on ≥3 drugs 58% 30% 50% 45% 12% <0.001
1 3 5 1 9 (18%) 65 (44%)
2 5 9 4 18 (37%) 65 (44%)
3 9 5 5 19 (39%) 13 (9%)
4 1 1 0 2 (4%) 4 (3%)
5 1 0 0 1 (2%) 0
Presence of target organ damage† (No. of patients)
Proteinuria‡ 1 2 1 4 (8%) 8 (5%) 0.16
CHF 2 0 0 2 (4%) 10 (7%) 0.49
IHD 2 1 0 3 (6%) 20 (14%) 0.16
CVA 1 1 2 4 (8%) 16 (11%) 0.59
LVH 7 4 1 12 (25%) 10 (7%) 0.001
Referral source (No. of patients)
GOPC 4 11 4 19 -
A&E 7 1 1 9 -
Private practitioner 1 0 0 1 -
MSOPC (FU for other 
reason)
7 8 5 20 -
* HT denotes hypertension, SD standard deviation, CHF congestive heart failure, IHD ischaemic heart disease, CVA cerebrovascular attack, LVH left ventricular 
hypertrophy, GOPC general out-patient clinic, A&E accident and emergency department, MSOPC medical specialist out-patient clinic, and FU follow-up
† Some patients had >1 type of target organ damage 
‡  Proteinuria was defined as persistent urine protein excretion of ≥300 mg/day
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3.95), and had a higher likelihood of left ventricular 
hypertrophy (OR=5.01; 95% CI, 1.83-13.69) [Table 2].
 Difference in the presence of other target 
organ damage, including cerebrovascular attack, 
ischaemic heart disease, congestive heart failure, 
and proteinuria (defined as persistent urine protein 
excretion of ≥300 mg/day) in the PH and EH patients 
were not statistically significant. Some patients had 
more than one target organ showing damage (5/49 PH 
and 15/147 EH patients). 
 The drugs used to treat PH patients with 
bilateral adrenal hyperplasia included aldosterone 
antagonists (eg spironolactone) or other potassium-
sparing diuretics (eg amiloride). For PH due to 
unilateral aldosterone-producing adenoma, the 
patients underwent unilateral adrenalectomy. 
 Among our 19 patients with confirmed Conn’s 
syndrome, 14 had adrenalectomies, four refused 
operation, and one defaulted follow-up. After 
adrenalectomy, pathology reports were available 
in 13 of our cases; all were confirmed to be adrenal 
adenomas. The operation was performed in China 
for the single case for which the pathology report 
was not available. 
 Postoperatively, 93% (13/14) had their 
potassium levels normalised. Regarding the single 
case of persistent hypokalaemia after unilateral 
adrenalectomy, about 1 year later the patient was 
found to have an adrenal adenoma on the other 
side and considered to have bilateral nodular 
adrenal hyperplasia. On the other hand, 93% 
(13/14) had improved blood pressure control after 
adrenalectomy (defined as a reduction of either ≥10 
mm Hg systolic or ≥5 mm Hg diastolic). Moreover, 
86% (12/14) enjoyed a reduction in the number of 
antihypertensive drugs they were taking; evidently 
50% (7/14) did not require any antihypertensive 
treatment. Before adrenalectomy, more than half 
of the patients with adrenal adenomas were taking 
three or more antihypertensive drugs for control 
of their hypertension, but after adrenalectomy the 
number was significantly reduced (P<0.001). Figure 2 
summarises the comparison of the antihypertensive 
drug use before and after adrenalectomy in patients 
with adrenal adenomas. 
Discussion 
The estimated percentage of PH among hypertensive 
patients in our locality was obviously very low 
compared to that in other countries, which may have 
been due to several contributing factors. First, ours 
was a retrospective estimate based on a computer 
coding system, the problem of under-coding of PH 
could have affected our findings. Second, we used 
to screen for PH in hypertensive patients only if they 
had unexplained hypokalaemia. Yet, studies showed 
that only about 38% of such patients present with 
hypokalaemia.18 Moreover, plasma ARR is currently 
recommended as the most reliable means of 
screening for PH.17-20 Third, our figure only included 
patients encountered in the public sector, whereas a 
proportion of PH patients could have been followed 
up in the private sector or seeing alternative medical 
practitioners. Fourth, ethnic differences could 
contribute to the apparent discrepancy, though 
the latest study from Singapore (only on Chinese 
patients) suggested a point prevalence of about 
5%.18 Notwithstanding above factors, there is a high 
probability that PH was significantly under-diagnosed 
in our locality. 
 Insufficient awareness of PH may have 
contributed to the situation of underdiagnosis. 
Increasing the awareness of the condition by primary 
care doctors and specialists appears necessary. 
Latest guidelines suggest that screening by ARR 
(not only those with hypokalaemia) can yield a 
relatively higher prevalence of PH.19,20 This should 
be undertaken for patients with drug-resistant 
hypertension, hypertension with spontaneous or 
diuretic-induced hypokalaemia, hypertension with 
adrenal incidentaloma, young-onset hypertension, 
* Only significant variables by forward stepwise logistic regression were reported
† Odds ratio <1 = less likely than the EH patients, odds ratio >1 = more likely than the EH 
patients; the Hosmer-Lemeshow test (P=0.589) indicates the good fit of data to logistic 
regression
TABLE 2.  Factors associated with hypertension type (primary hyperaldosteronism 
[PH] vs essential hypertension [EH]) by logistic regression analysis
Variable* Odds ratio† 95% Confidence 
interval
P value
Years with hypertension diagnosis 1.14 1.06-1.24 <0.001
Types of hypertensive drug ≥3 2.51 1.59-3.95 <0.001
Left ventricular hypertrophy 5.01 1.83-13.69 0.002
FIG 2.  Comparison of antihypertensive drug usage pre- and post-adrenalectomy
No. of antihypertensive drugs taken
N
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Post-adrenalectomy
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those suffering cerebrovascular accidents aged less 
than 40 years, and hypertension in a first-degree 
relative of PH patients.19 
 To improve the diagnosis rate, screening by 
ARR is suggested. However, due to cost concerns, 
limited access to such testing, as well as our own 
observations, we suggest the following patients be 
targeted: (1) young age of onset of hypertension, 
which could be suggestive of a secondary cause; 
(2) patients deemed to require three or more 
antihypertensive drugs for blood pressure control; 
(3) young and/or short-duration hypertensive 
patients with left ventricular hypertrophy. These 
suggestions are all compatible with findings from 
published studies on PH.8,9,12,19
 Doctors in GOPC in Hong Kong generally 
have no access to ARR testing. Primary care doctors 
should nevertheless act as the gatekeepers and 
coordinators to pick up high-risk patients and 
refer them accordingly. We suggest that patients 
with resistant hypertension and especially those 
diagnosed when relatively young could be referred 
to SOPDs for assessment and/or further work-up. 
To this end, we hope to increase the awareness of 
the condition among both primary care doctors and 
other physicians so that appropriate screening can 
be performed more frequently in high-risk patients. 
Notably however, an increased ARR is not in itself 
diagnostic, and PH must be confirmed by aldosterone 
suppression testing.
 About half of our PH patients were eventually 
found to have adrenal adenomas, which could be 
surgically cured; successful outcomes being noted 
after adrenalectomy. Similar outcomes have also 
been reported in the literature and are believed to 
be cost-effective in the long-run.18,19,22 
 Most of our patients enjoyed better blood 
pressure control with a reduction in the number 
of antihypertensive drugs they were using; some 
even ceased taking drugs after successful surgical 
treatment. Good blood pressure control can 
reduce cardiovascular complications, ischaemic 
heart disease, and stroke. Almost all patients with 
hypokalaemia had their abnormality corrected, which 
in turn reduced the risk of symptomatic hypokalaemia 
including muscle paralysis and arrhythmia. From the 
health care point of view, curative treatment of PH 
can reduce the long-term health care burden on our 
society. 
Conclusions 
Primary hyperaldosteronism was probably 
significantly underdiagnosed in our locality. Patients 
with PH are more likely to be younger and more drug-
resistant than EH patients. Since PH is potentially 
surgically curable, instead of screening hypokalaemic 
hypertensive patients only, we suggest screening all 
high-risk individuals by ARR, especially those with 
young age of onset and/or resistant hypertension. 
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